|
1.
|
Baggiolini M, Dewald B and Moser B: Human
chemokines: an update. Annu Rev Immunol. 15:675–705. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Rollins BJ: Chemokines. Blood. 90:909–928.
1997.PubMed/NCBI
|
|
3.
|
Goda S, Imai T, Yoshie O, et al:
CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to
endothelial cells through integrin-dependent and -independent
mechanisms. J Immunol. 164:4313–4320. 2000. View Article : Google Scholar
|
|
4.
|
Bazan JF, Bacon KB, Hardiman G, et al: A
new class of membrane-bound chemokine with a CX3C motif. Nature.
385:640–644. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Pan Y, Lloyd C, Zhou H, et al:
Neurotactin, a membrane-anchored chemokine upregulated in brain
inflammation. Nature. 387:611–617. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Fong AM, Robinson LA, Steeber DA, et al:
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte
capture, firm adhesion, and activation under physiologic flow. J
Exp Med. 188:1413–1419. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Combadiere C, Salzwedel K, Smith ED,
Tiffany HL, Berger EA and Murphy PM: Identification of CX3CR1. A
chemotactic receptor for the human CX3C chemokine fractalkine and a
fusion coreceptor for HIV-1. J Biol Chem. 273:23799–23804. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Imai T, Hieshima K, Haskell C, et al:
Identification and molecular characterization of fractalkine
receptor CX3CR1, which mediates both leukocyte migration and
adhesion. Cell. 91:521–530. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Nishiyori A, Minami M, Ohtani Y, et al:
Localization of fractalkine and CX3CR1 mRNAs in rat brain: does
fractalkine play a role in signaling from neuron to microglia? FEBS
Lett. 429:167–172. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Jamieson-Gladney WL, Zhang Y, Fong AM,
Meucci O and Fatatis A: The chemokine receptor CX3CR1 is directly
involved in the arrest of breast cancer cells to the skeleton.
Breast Cancer Res. 13:R912011. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Valdivia-Silva JE, Franco-Barraza J, Silva
AL, et al: Effect of pro-inflammatory cytokine stimulation on human
breast cancer: implications of chemokine receptor expression in
cancer metastasis. Cancer Lett. 283:176–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration, and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Jamieson WL, Shimizu S, D’Ambrosio JA,
Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial
cells and androgens regulate the levels of CX3CL1/fractalkine in
the bone marrow: potential role in prostate cancer bone tropism.
Cancer Res. 68:1715–1722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Marchesi F, Piemonti L, Fedele G, et al:
The chemokine receptor CX3CR1 is involved in the neural tropism and
malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res.
68:9060–9069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Nevo I, Sagi-Assif O, Meshel T, et al: The
involvement of the fractalkine receptor in the transmigration of
neuroblastoma cells through bone-marrow endothelial cells. Cancer
Lett. 273:127–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Andreasson U, Ek S, Merz H, et al: B cell
lymphomas express CX3CR1 a non-B cell lineage adhesion molecule.
Cancer Lett. 259:138–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Erreni M, Solinas G, Brescia P, et al:
Human glioblastoma tumours and neural cancer stem cells express the
chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer.
46:3383–3392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Rodero M, Marie Y, Coudert M, et al:
Polymorphism in the microglial cell-mobilizing CX3CR1 gene is
associated with survival in patients with glioblastoma. J Clin
Oncol. 26:5957–5964. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Gaudin F, Nasreddine S, Donnadieu AC, et
al: Identification of the chemokine CX3CL1 as a new regulator of
malignant cell proliferation in epithelial ovarian cancer. PLoS
One. 6:e215462011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
American Cancer Society: Cancer Facts and
Figures, 2011. American Cancer Society; Atlanta: 2011
|
|
21.
|
Freedland SJ: Screening, risk assessment,
and the approach to therapy in patients with prostate cancer.
Cancer. 117:1123–1135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ye XC, Choueiri M, Tu SM and Lin SH:
Biology and clinical management of prostate cancer bone metastasis.
Front Biosci. 12:3273–3286. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Hara T, Miyazaki H, Lee A, Tran CP and
Reiter RE: Androgen receptor and invasion in prostate cancer.
Cancer Res. 68:1128–1135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Rudolfsson SH and Bergh A: Hypoxia drives
prostate tumour progression and impairs the effectiveness of
therapy, but can also promote cell death and serve as a therapeutic
target. Expert Opin Ther Targets. 13:219–225. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Palayoor ST, Mitchell JB, Cerna D, Degraff
W, John-Aryankalayil M and Coleman CN: PX-478, an inhibitor of
hypoxia-inducible factor-1alpha, enhances radiosensitivity of
prostate carcinoma cells. Int J Cancer. 123:2430–2437. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Babar IA, Czochor J, Steinmetz A, Weidhaas
JB, Glazer PM and Slack FJ: Inhibition of hypoxia-induced miR-155
radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther.
12:908–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Pipinikas CP, Carter ND, Corbishley CM and
Fenske CD: HIF-1alpha mRNA gene expression levels in improved
diagnosis of early stages of prostate cancer. Biomarkers.
13:680–691. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Semenza GL and Wang GL: A nuclear factor
induced by hypoxia via de novo protein synthesis binds to the human
erythropoietin gene enhancer at a site required for transcriptional
activation. Mol Cell Biol. 12:5447–5454. 1992.PubMed/NCBI
|
|
29.
|
Koong AC, Chen EY and Giaccia AJ: Hypoxia
causes the activation of nuclear factor kappa B through the
phosphorylation of I kappa B alpha on tyrosine residues. Cancer
Res. 54:1425–1430. 1994.
|
|
30.
|
Wang Y, Li Z, Zhang H, et al: HIF-1alpha
and HIF-2alpha correlate with migration and invasion in gastric
cancer. Cancer Biol Ther. 10:376–382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Murphy PM: Chemokines and the molecular
basis of cancer metastasis. N Engl J Med. 345:833–835. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Lu Y, Cai Z, Galson DL, et al: Monocyte
chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine
factor for prostate cancer growth and invasion. Prostate.
66:1311–1318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Waugh DJ, Wilson C, Seaton A and Maxwell
PJ: Multi-faceted roles for CXC-chemokines in prostate cancer
progression. Front Biosci. 13:4595–4604. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Zhang S, Qi L, Li M, et al: Chemokine
CXCL12 and its receptor CXCR4 expression are associated with
perineural invasion of prostate cancer. J Exp Clin Cancer Res.
27:622008. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Gladson CL and Welch DR: New insights into
the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther.
7:1849–1851. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Wang J, Lu Y, Koch AE, Zhang J and
Taichman RS: CXCR6 induces prostate cancer progression by the
AKT/mammalian target of rapamycin signaling pathway. Cancer Res.
68:10367–10376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Xiao LJ, Lin P, Lin F, et al: ADAM17
targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to
promote prostate cancer cell invasion. Int J Oncol. 40:1714–1724.
2012.PubMed/NCBI
|
|
39.
|
Veldkamp CT, Peterson FC, Hayes PL, et al:
On-column refolding of recombinant chemokines for NMR studies and
biological assays. Protein Expr Purif. 52:202–209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Baggiolini M: Chemokines in pathology and
medicine. J Intern Med. 250:91–104. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Maxwell PJ, Gallagher R, Seaton A, et al:
HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2
expression promotes cell survival in hypoxic prostate cancer cells.
Oncogene. 26:7333–7345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Wilczynski J, Duechler M and Czyz M:
Targeting NF-kappaB and HIF-1 pathways for the treatment of cancer:
part I. Arch Immunol Ther Exp (Warsz). 59:289–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Wilczynski J, Duechler M and Czyz M:
Targeting NF-kappaB and HIF-1 pathways for the treatment of cancer:
part II. Arch Immunol Ther Exp (Warsz). 59:301–307. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Perkins ND: The diverse and complex roles
of NF-kappaB subunits in cancer. Nat Rev Cancer. 12:121–132.
2012.PubMed/NCBI
|
|
45.
|
Liu YL, Yu JM, Song XR, Wang XW, Xing LG
and Gao BB: Regulation of the chemokine receptor CXCR4 and
metastasis by hypoxia-inducible factor in non small cell lung
cancer cell lines. Cancer Biol Ther. 5:1320–1326. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Li Y, Qiu X, Zhang S, Zhang Q and Wang E:
Hypoxia induced CCR7 expression via HIF-1alpha and HIF-2alpha
correlates with migration and invasion in lung cancer cells. Cancer
Biol Ther. 8:322–330. 2009. View Article : Google Scholar : PubMed/NCBI
|
